EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma

Toni K Choueiri iD, Robert J Motzer, Jose A Karam, Wesley Yip, Cristina Suárez, Dingwei Ye, Zhisong He, Christian Caglevic, Tom Ferguson, Yen-Hwa Chang, Carlos Rojas, Roberto Iacovelli und 16 weitere

New England Journal of Medicine · 02.07.2026 · 395 (1) · 32-43

DOI: 10.1056/nejmoa2518245 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.07.2026. Verfasst von Toni K Choueiri und 27 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsNeoplasm Recurrence, LocalAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic Agents, ImmunologicalChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind MethodKaplan-Meier EstimateIndenesNephrectomyAdministration, OralInfusions, IntravenousYoung AdultAged, 80 and over

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalbelzutifanpembrolizumabIndenes

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston.
  • Harvard Medical School, Boston.
  • Memorial Sloan Kettering Cancer Center, New York.
  • University of Texas M.D. Anderson Cancer Center, Houston.
  • City of Hope Comprehensive Cancer Center, Duarte, CA.
  • Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona.

ORCID-Profile: Toni K Choueiri

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Choueiri, T. K., Motzer, R. J., Karam, J. A., Yip, W., Suárez, C., Ye, D., He, Z., Caglevic, C., Ferguson, T., Chang, Y. H., Rojas, C., Iacovelli, R., Ürün, Y., Verzoni, E., Vázquez Limón, J. C., Porta, C., Uzzo, R. G., Lee, J. L., Venugopal, B., …, & LITESPARK-022 Investigators (2026). Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. New England Journal of Medicine, 395(1), 32-43. https://doi.org/10.1056/nejmoa2518245

Vancouver

Choueiri TK, Motzer RJ, Karam JA, Yip W, Suárez C, Ye D, et al. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. New England Journal of Medicine. 2026;395(1):32-43. doi:10.1056/nejmoa2518245

BibTeX
@article{Choueiri2026,
  author = {Choueiri, Toni K and Motzer, Robert J and Karam, Jose A and Yip, Wesley and Suárez, Cristina and Ye, Dingwei and He, Zhisong and Caglevic, Christian and Ferguson, Tom and Chang, Yen-Hwa and Rojas, Carlos and Iacovelli, Roberto and Ürün, Yüksel and Verzoni, Elena and Vázquez Limón, Juan Carlos and Porta, Camillo and Uzzo, Robert G and Lee, Jae Lyun and Venugopal, Balaji and McKay, Rana R and Hammers, Hans and Miyake, Hideaki and Chahoud, Jad and Liu, Hong and Burgents, Joseph E and Sharma, Manish and Powles, Thomas B and LITESPARK-022 Investigators, LITESPARK-022 Investigators},
  title = {Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {1},
  pages = {32--43},
  doi = {10.1056/nejmoa2518245}
}
Kostenlos starten →